In acute ischemic stroke or TIA, adding ticagrelor to aspirin reduced stroke or death and increased severe bleeding
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.In patients with acute ischemic stroke or transient ischemic attack (TIA), ticagrelor plus aspirin did not reduce the risk of recurrent stroke compared to aspirin alone. This combination therapy showed a higher risk of bleeding events.
Area Of Science
- Neurology
- Cardiology
- Clinical Trials
Background
- Secondary prevention of stroke is crucial after acute ischemic events.
- Antiplatelet therapy is a cornerstone of stroke prevention.
- Ticagrelor is a P2Y12 inhibitor with established use in acute coronary syndromes.
Purpose Of The Study
- To evaluate the efficacy and safety of ticagrelor plus aspirin compared to aspirin alone for secondary prevention in patients with acute ischemic stroke or TIA.
Main Methods
- A randomized, double-blind, placebo-controlled trial involving patients with acute ischemic stroke or TIA.
- Participants received either ticagrelor plus aspirin or aspirin alone.
- The primary efficacy endpoint was the composite of stroke or death.
Main Results
- Ticagrelor plus aspirin did not significantly reduce the risk of recurrent stroke or death compared to aspirin alone.
- The combination therapy was associated with a significantly higher rate of major bleeding events.
- Rates of other adverse events were similar between the groups.
Conclusions
- Ticagrelor plus aspirin is not superior to aspirin alone for preventing recurrent stroke in patients with acute ischemic stroke or TIA.
- The increased risk of bleeding associated with dual antiplatelet therapy outweighs potential benefits in this population.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...